Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes adverse Events, compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyRR 2.84 [0.96, 8.37]1 study · 142 participantsVery low